ArticleClinical and translational radiation oncology2027
Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience.
Article in Clinical and translational radiation oncology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Local recurrence in prostate cancer (PCa) after radical radiotherapy has become increasingly prevalent in the era of next-generation imaging. Meta-analyses suggest a favourable adverse event (AE) profile for stereotactic body radiotherapy (SBRT). This study aimed to evaluate the safety and efficacy of high-precision daily adaptive 1.5 T MR-Linac re-irradiation (re-EBRT). Methods: This international retrospective study evaluated outcomes in patients with locally radio-recurrent PCa treated with adaptive SBRT re-EBRT on a 1.5 T MR-Linac platform. Eligible patients had biochemically or histologically confirmed radiological local recurrence within the previously irradiated prostate or prostate bed. Clinical characteristics, treatment, AE, and follow-up data were summarised using descriptive statistics and Kaplan-Meier methods. Results: Seventy five patients were included across four centres. The median interval from primary radical therapy to recurrence was 79.0 months (IQR 56.2-126.5). Median PSA at initial presentation was 8.1 ng/mL (IQR 6.0-11.8), with a median PSA at recurrence of 2.2 ng/mL (IQR 1.0-3.6). Median age at re-EBRT was 73.3 years (IQR 68.5-77.7). MRI-guided adaptive radiotherapy (MRIgART) was delivered with hypofractionated regimens, most commonly 30 Gy in 5 fractions, with 46.7% receiving focal (GTV-only) and 53.3% whole-gland treatment. At 3 months, genitourinary AE were Grade 0-1 in 85.3% (64/75) of patients, Grade 2 in 13.3% (10/75) and Grade 3 AE in 1.3% (1/75). By 12 months, Grade 3 AE had risen to 12.5% (6/48), with no Grade ≥ 4 events. Gastrointestinal AE were mild, with no Grade 2 or higher events observed at any timepoint. Median post-re-EBRT follow-up was 11.9 months (IQR 3.5-21.1 months). Failure-free survival was 96.6% (95% CI 92.0-100.0) at 12 months and 76.5% (95% CI 62.8-93.2) at 24 months. The failures observed occurred within 24 months and were confined to intraprostatic/prostate bed or seminal vesicle sites. Conclusions: MRIgART re-EBRT is feasible for locally recurrent PCa, with acceptable gastrointestinal but non-negligible short to medium-term genitourinary toxicity.Data sharing statement: Research data are not available at this time. All centres subscribe to the MOMENTUM registry, from which data access requests can be made by participating centres.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.